SuperworthPasithea Therapeutics EPS KTTA
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$1.49
- Latest quarter, Q2 FY26
- −$0.16
- Fiscal year 2025
- −$3.48
Pasithea Therapeutics' earnings per share was −$1.49 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.16.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.48 | n/a |
| FY2024 | −$12.82 | n/a |
| FY2023 | −$13.31 | n/a |
| FY2022 | −$10.60 | n/a |
| FY2021 | −$5.80 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.16 | n/a | −$1.49 | |
| Q1 FY26 | −$0.12 | n/a | −$1.99 | |
| Q4 FY25 | −$0.80 | n/a | −$3.48 | |
| Q3 FY25 | −$0.41 | n/a | −$5.22 | |
| Q2 FY25 | −$0.66 | n/a | −$7.68 | |
| Q1 FY25 | −$1.61 | n/a | −$10.73 | |
| Q4 FY24 | −$2.54 | n/a | −$12.82 | |
| Q3 FY24 | −$2.87 | n/a | −$15.13 | |
| Q2 FY24 | −$3.71 | n/a | −$15.13 | |
| Q1 FY24 | −$3.70 | n/a | −$14.30 | |
| Q4 FY23 | −$4.85 | n/a | −$13.31 | |
| Q3 FY23 | −$2.87 | n/a | −$12.06 |
Against its peers
Companies in Drug Manufacturers - General nearest Pasithea Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KTTAPasithea Therapeutics | −$1.49 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Pasithea Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.